Putting The Emphasis On Heart Failure In Chicago

EMPHASIS heart failure study will reveal a lot with a medicine already FDA approved

On Sunday, a late breaking clinical trial called EMPHASIS HF will give critical new information on a medicine called Inspra (eplerenone) and the benefits it will have in heart failure. This medicine is already FDA approved and we already know that the study was suspended before it enrolled the expected number of patients because the people who were getting the medicine got such great results.

This well-designed study early peak (interim analysis) showed that the NYHA class two heart failure patients had an important decrease in risk of going to the hospital for heart failure or from dying from heart or blood vessel (cardiovascular) disease.

Contact Us